Lumexa Imaging (NASDAQ:LMRI) Director Brett Brodnax Acquires 35,000 Shares

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Director Brett Brodnax purchased 35,000 shares of Lumexa Imaging stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average cost of $7.25 per share, for a total transaction of $253,750.00. Following the purchase, the director directly owned 62,027 shares in the company, valued at $449,695.75. This trade represents a 129.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Lumexa Imaging Price Performance

LMRI stock traded up $0.78 during trading on Thursday, hitting $8.18. The company had a trading volume of 940,684 shares, compared to its average volume of 896,240. Lumexa Imaging Holdings, Inc. has a 52-week low of $6.45 and a 52-week high of $19.45. The firm has a 50 day moving average of $9.87.

Hedge Funds Weigh In On Lumexa Imaging

Institutional investors have recently bought and sold shares of the business. Readystate Asset Management LP raised its position in Lumexa Imaging by 60.5% during the 1st quarter. Readystate Asset Management LP now owns 224,755 shares of the company’s stock worth $1,933,000 after buying an additional 84,755 shares during the last quarter. Sei Investments Co. raised its position in Lumexa Imaging by 339.6% during the 1st quarter. Sei Investments Co. now owns 88,190 shares of the company’s stock worth $758,000 after buying an additional 68,127 shares during the last quarter. State of Wyoming purchased a new position in Lumexa Imaging during the 1st quarter worth approximately $91,000. PNC Financial Services Group Inc. purchased a new position in Lumexa Imaging during the 1st quarter worth approximately $63,000. Finally, Emerald Mutual Fund Advisers Trust raised its position in Lumexa Imaging by 11.0% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 653,342 shares of the company’s stock worth $5,619,000 after buying an additional 64,677 shares during the last quarter.

Wall Street Analysts Forecast Growth

LMRI has been the topic of several recent analyst reports. Barclays cut their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a report on Wednesday. Raymond James Financial upgraded shares of Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 price objective on the stock in a report on Monday, February 9th. Finally, Weiss Ratings initiated coverage on shares of Lumexa Imaging in a report on Wednesday, May 13th. They set a “sell (e-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).